Clinical Trial: BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy

U.S., Oct. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07869836) titled 'BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy' on Oct. 06.

Brief Summary: The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Urothelial Cancer Metastatic Urothelial Cancer Bladder Cancer Bladder Cancer (BC) Bladder (Urothelial, Transitional Cell) Cancer Bladder (Urothelial, Transitional ...